Management of residual masses in testicular germ cell tumors

References

• Albers P, Albrecht W, Algaba F, et al. European association of urology. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68:1054–1068.
   PubMed Web of Science ®Google Scholar
• Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29:1658–1686.
   PubMed Web of Science ®Google Scholar
• Daneshmand S, Albers P, Fosså SD, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012;62:867–876.
   PubMed Web of Science ®Google Scholar
• Woldu SL, Matulay JT, Clinton TN, et al. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol. 2018;36:14.e7-e15.
   Web of Science ®Google Scholar
• Flechon A, Bompas E, Biron P, et al. Management of post-chemotherapy residual masses in advanced seminoma. J Urol. 1979;168:1975–1979.
   Google Scholar
• Friedman EL, Garnick MB, Stomper PC, et al. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol. 1985;3:1325–1332.
   PubMed Web of Science ®Google Scholar
• Schultz SM, Einhorn LH, Conces DJ, et al. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol. 1989;7:1497–1503.
   PubMed Web of Science ®Google Scholar
• Fosså SD, Borge L, Aass N, et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol. 1987 Jul;5(7):1071–1077.
   PubMed Web of Science ®Google Scholar
• Ravi R, Rao RR, Shanta V. Integrated approach to the management of patients with advanced germ cell tumors of the testis. J Surg Oncol. 1994 Jan;55(1):47–51.
   PubMed Web of Science ®Google Scholar
• Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol. 1996;14:454–460.
   PubMed Web of Science ®Google Scholar
• Mosharafa AA, Foster RS, Leibovich CC, et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol. 2003;169:2126–2128.
   PubMed Web of Science ®Google Scholar
• Pfister D, Porres D, Matveev V, et al. Reduced morbidity in resection of residual tumors after chemotherapy for seminoma. Urologe A. 2015;54:1402–1406.
   PubMedGoogle Scholar
• De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update from the multicenter SEMPET trial. J Clin Oncol. 2004;22:1034–1039.
   PubMed Web of Science ®Google Scholar
• Becherer A, De Santis M, Karanikas G, et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 2005;54:284–288.
   PubMed Web of Science ®Google Scholar
• Albers P, Weissbach L, Krege S, et al. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol. 2004;171:1835–1838.
   PubMed Web of Science ®Google Scholar
• Kamat MR, Kulkarni JN, Tongoankar HB, et al. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol. 1992;51:65–67.
   PubMed Web of Science ®Google Scholar
• Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int. 1996;57:38–42.
   PubMed Web of Science ®Google Scholar
• Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 1997;157:860–862.
   PubMed Web of Science ®Google Scholar
• Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28:531–536.
   PubMed Web of Science ®Google Scholar
• Pfister D, Haidl F, Paffenholz P, et al. Metastatic surgery in testis cancer. Curr Opin Urol. 2016 Nov;26(6):590–595.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Daneshmand S, So A, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol. 2010;28(4):537–542.
   PubMed Web of Science ®Google Scholar
• Albers P, Höltl W, Heidenreich A, et al. Thoracoabdominal resection of retrocrural residual tumors. Akt Urol. 2004;35:141–150.
   PubMed Web of Science ®Google Scholar
• Fujioka T, Nomura K, Okamoto T, et al. Retroperitoneal lymph node dissection for testicular tumors using the thoracoabdominal approach. Int Surg. 1993;78:154–158.
   PubMed Web of Science ®Google Scholar
• Skinner DG, Melamud A, Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymph node dissection. J Urol. 1982;127:1107–1110.
   PubMed Web of Science ®Google Scholar
• Wood DP, Herr HW, Heller G, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol. 1992;148:1812–1816.
   PubMedGoogle Scholar
• Heidenreich A, Haidl F, Paffenholz P, et al. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol. 2017;28:362–367.
   PubMed Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R, et al. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2001;165:1517–1520.
   PubMed Web of Science ®Google Scholar
• Winter C, Pfister D, Busch J, et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;6:403–409.
   Google Scholar
• Johnston P, Beck SD, Cheng L, et al. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013;190:874–878.
   PubMed Web of Science ®Google Scholar
• Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998;82:1343–1351.
   PubMed Web of Science ®Google Scholar
• Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668–1676.
   PubMed Web of Science ®Google Scholar
• Qvist HL, Fossa SD, Ous S, et al. Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol. 1991;145:300–302.
   PubMed Web of Science ®Google Scholar
• Rabbani F, Goldenberg SL, Gleave ME, et al. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of the residual mass sufficient? Br J Urol. 1998;81:295–300.
   PubMedGoogle Scholar
• Aprikian AG, Herr HW, Bajorin DF, et al. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994;74:1329–1334.
   PubMed Web of Science ®Google Scholar
• Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol. 1997;80:653–657.
   PubMedGoogle Scholar
• Beck SD, Foster RS, Bihrle R, et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer. 2007;110:1235–1240.
   PubMed Web of Science ®Google Scholar
• Cho JS, Kaimakliotis HZ, Cary C, et al. Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. BJU Int. 2017;120:104–108.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Witthuhn R, et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55:217–224.
   PubMed Web of Science ®Google Scholar
• Vallier C, Savoie PH, Delpero JR, et al. External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol. 2014;32:1573–1578.
   PubMed Web of Science ®Google Scholar
• Ehrlich Y, Yossepovitch O, Kedar D, et al. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int. 2006;97:1221–1224.
   PubMed Web of Science ®Google Scholar
• Krege S, Beyer J, Souchon R, et al. European consensus conference ondiagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53:478–496.
   PubMed Web of Science ®Google Scholar
• Besse B, Grunenwald D, Flechon A, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thoracic Cardiovasc Surg. 2009;137:448–452.
   PubMed Web of Science ®Google Scholar
• Masterson TA, Carver BS, Shayegan B, et al. Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. Urology. 2012;79:1079–1084.
   PubMed Web of Science ®Google Scholar
• Hahn T, Jacobson L, Einhorn L, et al. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol. 1999;6:640–644.
   PubMed Web of Science ®Google Scholar
• Rivoire M, Elias D, De Cian F, et al. Multimodality treatment of patients with liver metastases from germ cell tumours. Cancer. 2001;92:578–587.
   PubMed Web of Science ®Google Scholar
• Jacobsen N, Beck S, Jacobsen L, et al. Is retroperitoneal History predictive of liver histology at concurrent postchemotherapy retroperitoneal lymph node dissection and hepatic resection. J Urol. 2010;184:949–953.
   PubMed Web of Science ®Google Scholar
• Copson E, McKendrick J, Hennessey N, et al. Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy. BJU Int. 2004;94:552–558.
   PubMed Web of Science ®Google Scholar
• Uygun K, Karagol H, Kocak Z, et al. Isolated bone metastasis in testicular germ cell tumors: a case report and review of the literature. Onkologie. 2006;29:93–95.
   PubMedGoogle Scholar
• Berglund R, Lyden S, Tsai E, et al. Nonesminomatous germ cell tumor after chemotherapy with residual mass invading the spine. Eur Urol. 2006;50:372–374.
   PubMed Web of Science ®Google Scholar
• Hitchins R, Philip P, Wignall B, et al. Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer. 1988;58:793–796.
   PubMed Web of Science ®Google Scholar
• Oing C, Oechsle K, Necchi A, et al. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 registry study. Ann Oncol. 2017;28:576–582.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Bokemeyer C. Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am. 2011;25:605–613.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study. J Clin Oncol. 2001;19:2647–2657.
   PubMed Web of Science ®Google Scholar
• Iida K, Naiki T, Kawai N, et al. Metastasectomy as optimal treatment for late relapsing solitary brain metastasis from testicular germ cell tumor: a case report. BMC Res Notes. 2014;7:865.
   PubMedGoogle Scholar
• Loriot Y, Pagliaro L, Fléchon A, et al. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: implications for assessment of brain metastases. Eur J Cancer. 2017;87:140–146.
   PubMed Web of Science ®Google Scholar
• Girones R, Aparicio J, Roure P, et al. Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base. Clin Transl Oncol. 2014;16:959–965.
   PubMed Web of Science ®Google Scholar
• Eggener S, Carver BS, Loeb S, et al. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimes for metastatic testicular germ cell tumors. Cancer. 2007;109:528–535.
   PubMed Web of Science ®Google Scholar
• Waples MJ, Messing EM. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology. 1993;42:1–4.
   Web of Science ®Google Scholar
• Cespedes RD, Peretsman SJ. Retroperitoneal recurrences after retroperitoneal lymph node dissection for low-stage nonseminomatous germ cell tumors. Urology. 1999;54:548–552.
   PubMed Web of Science ®Google Scholar
• Sexton WJ, Wood CG, Kim R, et al. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol. 2003;169:1353–1356.
   PubMed Web of Science ®Google Scholar
• McKiernan JM, Motzer RJ, Bajorin DF, et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence and outcome. Urology. 2003;62:732–736.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Ohlmann C, Hegele A, et al. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol. 2005;47:64–71.
   PubMed Web of Science ®Google Scholar
• Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated markers. J Urol. 2000;164:381–384.
   PubMed Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R, et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23:6149–6156.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve-sparing lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol. 2003;169:1710–1714.
   PubMed Web of Science ®Google Scholar
• Mosharafa AA, Foster RS, Koch MO, et al. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171:1839–1841.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Oldenburg J, Dunant A, et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol. 2008 Feb;19(2):259–64.
   PubMed Web of Science ®Google Scholar